David A. Siegel Crinetics Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 33,600 shares of CRNX stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,600
Previous 31,800
5.66%
Holding current value
$1.82 Million
Previous $1.49 Million
1.08%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$337 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$330 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$250 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$244 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$238 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.91B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...